The management of metastatic uveal melanoma still presents a major clinical challenge, and it is important for healthcare providers to be aware of the most current recommendations by the NCCN Panel.

This program will provide expert insights on the current recommendations of care for patients with breast cancer and include the latest clinical research updates to assist clinicians in formulating breast cancer management strategies.

In order to optimize overall patient outcomes, clinicians need to understand the evidence behind the current guidelines’ recommendations, the rationale for appropriate treatment selection, and the management of any treatment- or multiple myeloma-specific adverse events.

It is difficult for clinicians to stay current with the evolving treatment options for colorectal cancer, and they can benefit from education about these therapies.

Clinicians must be trained to use assessment tools and stay abreast of the trial data that are available to improve morbidity and mortality in those over 60 or 65. Pharmacists have the opportunity now to improve treatment outcomes and communication between patient and provider, so the patient receives the best care for their situation and goals.

Being familiar with the current management of breast cancer will help clinicians support their patients and to communicate with specialists in the multidisciplinary team.

Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.

The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.

Pharmacists should be aware of the new data and recommendations surrounding novel agents and how they relate to improvements in patient survival and quality of life. It is also important to be aware of the potential for unique and potentially severe adverse events that can occur with these therapies.

Education on the appropriate use of newly approved therapies and considerations for treatment planning and side effect management can benefit clinicians interested in incorporating these therapies into their clinical practice.